-
April 14, 2021 GH Research Raises $125 Million to Fund DMT Treatment for DepressionGH Research closed a $125 million Series B financing round to fund the advancement of...
-
April 14, 2021 First-Ever Jewish Psychedelic Summit Planned for May 2-3The first conference of its kind, the Jewish Psychedelic Summit, will explore the connection between...
-
April 14, 2021 Silo Wellness Expands Shareholder Base to EuropeToronto's Silo Wellness is now trading on the German Stock Exchange as demand for psychedelic...
-
April 13, 2021 Daniel Carcillo’s Psychedelic Startup Wesana Health Raises More Funds, On Track to Go PublicFormer NHL player Daniel Carcillo's psychedelic startup Wesana Health is preparing to take the company...
-
April 12, 2021 Ketamine Therapy Shows Benefits in Treating Depression Related to Childhood AbuseAdults with depression who were abused or neglected as children responded better to intravenous ketamine...
-
April 12, 2021 Psychedelics Company Atai Adds Brain-Computer Interface for Mental Health TreatmentAtai Life Sciences is working to combine psychedelics with brain-computer interfaces for mental health treatment.
-
April 9, 2021 Psychedelic Business News Spotlight: April 9, 2021This week in psychedelic business news: a psilocybin delivery system for brain inflammation, a genetic...
-
April 8, 2021 Psychedelic Conference to Explore Promising Therapies for Veterans, First RespondersThe Heroic Dose conference will explore the use of psychedelic therapies to treat post-traumatic stress...
-
April 8, 2021 Mydecine Prepares to Present Four Novel Psychedelic CandidatesColorado-based Mydecine is launching four new psychedelic candidates for use in treating conditions like anxiety...
-
April 7, 2021 Yale to Study Psilocybin for Cluster HeadachesPsilocybin is showing relief as treatment for cluster headaches — a painful condition that affects...
